Explore the Global Prophylactic HIV Drugs Market — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036

Future Market Insights

Prophylactic HIV Drugs Market

Key Insight

Prophylactic HIV drugs sales will grow through 2036, led by nucleoside reverse transcriptase inhibitors at a 50% share in 2026 as the leading drug class segment. The market was valued at USD 35.20 billion in 2025 and is expected to reach USD 57.12 billion by 2036, creating an incremental opportunity of USD 20.34 billion.

May 29, 2026

Anurag Sharma

250 Pages

Cite this Report

Prophylactic HIV Drugs Market

https://www.futuremarketinsights.com/reports/prophylactic-hiv-drugs-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Apotex Inc
Aurobindo Pharma
Cipla Ltd
Gilead Sciences
Hetero Healthcare
The Vanguard Group
Lupin
Merck KGaA
Mylan N.V
Berkshire Hathaway
ViiV Healthcare

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Prophylactic HIV Drugs Market

Key Players

Similar Industry Reports